Enliven Grants CEO Richard Fair 875,000 Stock Options at $18.77 Each
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 39 minutes ago0mins
- Executive Incentive Plan: Enliven Therapeutics granted 875,000 stock options to new CEO Richard Fair at an exercise price of $18.77 per share, aimed at attracting him to the company and driving business growth.
- Vesting Arrangement: The stock options will vest gradually starting December 11, 2026, with 25% vesting in the first year and 1/48th monthly thereafter, ensuring Fair's ongoing contributions during his tenure.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in executive compensation.
- Strategic Development Goals: Enliven focuses on developing small molecule therapeutics, aiming to address unmet medical needs through a precision oncology approach that enhances patient survival and quality of life.
ELVN.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 39.50 USD with a low forecast of 35.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.170
Low
35.00
Averages
39.50
High
48.00
Current: 20.170
Low
35.00
Averages
39.50
High
48.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$40 -> $48
2025-07-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $48
2025-07-02
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Enliven to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become "the go-to agent" in chronic myelogenous leukemia.
Goldman Sachs
Salveen Richter
NULL -> Buy
upgrade
$37
2025-06-17
Reason
Goldman Sachs
Salveen Richter
Price Target
$37
2025-06-17
upgrade
NULL -> Buy
Reason
Goldman Sachs analyst Salveen Richter assigned of Enliven with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company's continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.
Baird
Colleen Kusy
Outperform
maintain
$40 -> $52
2025-06-17
Reason
Baird
Colleen Kusy
Price Target
$40 -> $52
2025-06-17
maintain
Outperform
Reason
Baird analyst Colleen Kusy raised the firm's price target on Enliven to $52 from $40 and keeps an Outperform rating on the shares. The firm updated its model as its ELVN-001 data continues to show improvement which supports its compelling profile.
JonesResearch
Soumit Roy
Buy
downgrade
$36 -> $27
2025-05-16
Reason
JonesResearch
Soumit Roy
Price Target
$36 -> $27
2025-05-16
downgrade
Buy
Reason
See All Ratings
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?